Dentin matrix protein 1 induces membrane expression of VE-cadherin on endothelial cells and inhibits VEGF-induced angiogenesis by blocking VEGFR-2 phosphorylation

Blood

Volumn 117, Issue 8, 2011, Pages 2515-2526

  Pirotte, Sophie ^a   Lamour, Virginie ^a   Lambert, Vincent ^b,c   Gonzalez, Maria Luz Alvarez ^b   Ormenese, Sandra ^d   Noël, Agnès ^b   Mottet, Denis ^a   Castronovo, Vincent ^a   Bellahcène, Akeila ^a  

^a Bat B23   (Belgium)

^b Grappe Disciplinaire de Génoprotéomique Appliquée   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; DENTIN MATRIX PROTEIN 1; FIBROBLAST GROWTH FACTOR; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE ARREST; CELL GROWTH; CELL JUNCTION; CELL MIGRATION; CELL PROLIFERATION; CHOROID VASCULARIZATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; RETINA NEOVASCULARIZATION; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAIN; UMBILICAL VEIN ENDOTHELIAL CELL;

EID: 79952164899     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-08-298810     Document Type: Article

References (44)

1. Bellahcène A, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer. 2008;8(3):212-226.
2. Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun. 2001;280(2):460-465.
3. George A, Sabsay B, Simonian PA, Veis A. Characterization of a novel dentin matrix acidic phosphoprotein. Implications for induction of biomineralization. J Biol Chem. 1993;268(17):12624-12630.
4. Ogbureke KU, Fisher LW. Expression of SIBLINGs and their partnermMPs in salivary glands. J Dent Res. 2004;83(9):664-670.
5. Ogbureke KU, Fisher LW. Renal expression of SIBLING proteins and their partner matrix metalloproteinases (MMPs). Kidney Int. 2005;68(1):155-166.
6. Ling Y, Rios HF, Myers ER, Lu Y, Feng JQ, Boskey AL. DMP1 depletion decreases bone mineralization in vivo: an FTIR imaging analysis. J Bone Miner Res. 2005;20(12):2169-2177.
7. Fisher LW, Jain A, Tayback M, Fedarko NS. Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers. Clin Cancer Res. 2004;10(24):8501-8511.
8. Chaplet M, De Leval L, Waltregny D, et al. Dentin matrix protein 1 is expressed in human lung cancer. J Bone Miner Res. 2003;18(8):1506-1512.
9. Bucciarelli E, Sidoni A, Bellezza G, et al. Low dentin matrix protein 1 expression correlates with skeletal metastases development in breast cancer patients and enhances cell migratory capacity in vitro. Breast Cancer Res Treat. 2007;105(1):95-104.
10. Chaplet M, Waltregny D, Detry C, Fisher LW, Castronovo V, Bellahcene A. Expression of dentin sialophosphoprotein in human prostate cancer and its correlation with tumor aggressiveness. Int J Cancer. 2006;118(4):850-856.
11. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. Cancer Res. 1986;46(2):467-473.
12. Lampugnani MG, Resnati M, Raiteri M, et al. A novel endothelial-specific membrane protein is a marker of cell-cell contacts. J Cell Biol. 1992;118(6):1511-1522.
13. Carmeliet P, Lampugnani MG, Moons L, et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell. 1999;98(2):147-157.
14. Lampugnani MG, Zanetti A, Corada M, et al. Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, beta-catenin, and the phosphatase DEP-1/CD148. J Cell Biol. 2003;161(4):793-804.
15. Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J, Cheresh DA. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell. 1999;4(6):915-924.
16. Baumeister U, Funke R, Ebnet K, Vorschmitt H, Koch S, Vestweber D. Association of Csk to VE-cadherin and inhibition of cell proliferation. EMBO J. 2005;24(9):1686-1695.
17. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994;264(5158):569-571.
18. von Marschall Z, Fisher LW. Dentin matrix protein-1 isoforms promote differential cell attachment and migration. J Biol Chem. 2008;283(47):32730- 32740.
19. Jain A, Karadag A, Fohr B, Fisher LW, Fedarko NS. Three SIBLINGs (small integrin-binding ligand, N-linked glycoproteins) enhance factor H's cofactor activity enabling MCP-like cellular evasion of complement-mediated attack. J Biol Chem. 2002;277(16):13700-13708.
20. Savani RC, Cao G, Pooler PM, Zaman A, Zhou Z, DeLisser HM. Differential involvement of the hyaluronan (HA) receptors CD44 and receptor for HA-mediated motility in endothelial cell function and angiogenesis. J Biol Chem. 2001;276(39):36770-36778.
21. Cui R, Takahashi F, Ohashi R, et al. Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice. Lung Cancer. 2007;57(3):302-310.
22. Bellahcène A, Bonjean K, Fohr B, et al. Bone sialoprotein mediates human endothelial cell attachment and migration and promotes angiogenesis. Circ Res. 2000;86(8):885-891.
23. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973;52(11):2745-2756.
24. Lambert V, Munaut C, Noel A, et al. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J. 2001;15(6):1021-1027.
25. Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003; 44(7):3186-3193.
26. Lamour V, Le Mercier M, Lefranc F, et al. Selective osteopontin knockdown exerts anti-tumoral activity in a human glioblastoma model. Int J Cancer. 2010;126(8):1797-1805.
27. Hagedorn M, Javerzat S, Gilges D, et al. Accessing key steps of human tumor progression in vivo by using an avian embryo model. Proc Natl Acad Sci U S A. 2005;102(5):1643-1648.
28. Wang G, Miskimins R, Miskimins WK. Mimosine arrests cells in G1 by enhancing the levels of p27(Kip1). Exp Cell Res. 2000;254(1):64-71.
29. Ishida N, Kitagawa M, Hatakeyama S, Nakayama K. Phosphorylation at serine 10, a major phosphorylation site of p27(Kip1), increases its protein stability. J Biol Chem. 2000;275(33):25146-25154.
30. Levenberg S, Yarden A, Kam Z, Geiger B. p27 is involved in N-cadherin-mediated contact inhibition of cell growth and S-phase entry. Oncogene. 1999;18(4):869-876.
31. St Croix B, Sheehan C, Rak JW, Florenes VA, Slingerland JM, Kerbel RS. E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J Cell Biol. 1998;142(2):557-571.
32. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9(6):653-660.
33. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-676.
34. Brown MT, Cooper JA. Regulation, substrates and functions of src. Biochim Biophys Acta. 1996;1287(2-3):121-149.
35. Esser S, Lampugnani MG, Corada M, Dejana E, Risau W. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci. 1998;111(pt 13):1853-1865.
36. Levinson NM, Visperas PR, Kuriyan J. The tyrosine kinase Csk dimerizes through Its SH3 domain. PLoS One. 2009;4(11):e7683.
37. Kwak N, Okamoto N,Wood JM, Campochiaro PA. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41(10):3158-3164.
38. Gadhoum Z, Leibovitch MP, Qi J, et al. CD44: a new means to inhibit acute myeloid leukemia cell proliferation via p27Kip1. Blood. 2004;103(3):1059-1068.
39. Motti ML, Califano D, Baldassarre G, et al. Reduced E-cadherin expression contributes to the loss of p27kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas. Carcinogenesis. 2005;26(6):1021-1034.
40. Bach TL, Barsigian C, Chalupowicz DG, et al. VE-Cadherin mediates endothelial cell capillary tube formation in fibrin and collagen gels. Exp Cell Res. 1998;238(2):324-334.
41. Corada M, Liao F, Lindgren M, et al. Monoclonal antibodies directed to different regions of vascular endothelial cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeability. Blood. 2001;97(6):1679-1684.
42. Calera MR, Venkatakrishnan A, Kazlauskas A. VE-cadherin increases the half-life of VEGF receptor 2. Exp Cell Res. 2004;300(1):248-256.
43. Ha CH, Bennett AM, Jin ZG. A novel role of vascular endothelial cadherin in modulating c-Src activation and downstream signaling of vascular endothelial growth factor. J Biol Chem. 2008;283(11):7261-7270.
44. Wallez Y, Cand F, Cruzalegui F, et al. Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site. Oncogene. 2007;26(7):1067-1077.